Cetuximab in the treatment of colorectal cancer

Future Oncology

Volumn 1, Issue 2, 2005, Pages 173-181

  Ciardiello, Fortunato ^a   De Vita, Ferdinando ^a   Orditura, Michele ^a   Comunale, Daniela ^a   Galizia, Gennaro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

cetuximab; colorectal cancer; epidermal growth factor receptor targeted therapy; epidermal growth factor receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

COLORECTAL TUMOR; DRUG ANTAGONISM; FORECASTING; HUMAN; PATHOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FORECASTING; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27744491149     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.2.173     Document Type: Article

References (51)

1. Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P: New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100 (8), 1558-1577 (2004)
2. Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19(18), 32-40 (2001)
3. Salomon DS,Brandt R, Ciardiello F, Normanno N: Epidermal growth factorrelated peptides and their receptors in human malignancies. Crit. Rev. Oncol. Haematol. 19, 183-232 (1995)
4. Salomon DS, Gullick W: The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2, 4-11 (2001)
5. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-67 (2001)
6. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nature Rev. Mol. Cell. Biol. 2, 127-137 (2001)
7. McClelland RA, Barrow D, Madden T-A et al.: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142, 2776-2788 (2001)
8. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 5, 2884-2890 (1999)
9. Wosikowski K, Schuuruis D, Kops GJPL, Saceda M, Bates SE: Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. 3, 2405-2414 (1997)
10. Mendelsohn J: Blockade of receptors for growth factors: an anticancer therapy. Clin. Cancer Res. 6, 747-753 (2000)
11. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr. Related Cancer 8, 3-9 (2001)
12. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958-2970 (2001)
13. Grunwald V, Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst. 95, 851-867 (2003)
14. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799 (2003)
15. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor positive tumours: a new paradigm for cancer therapy. Cancer 94, 1593-1611 (2002)
16. Kim ES, Khuri FR, Herbst RS: Epidermal growth factor receptor biology (IMCC225). Curr. Opin. Oncol. 13(6), 506-513 (2001)
17. Ciardiello F, Tortora G: Anti-epidermal growth receptor drugs in cancer therapy. Expert Opin. Investig. Drugs 11(6), 755-768 (2002)
18. Humblet Y: Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor expressing tumours. Expert Opin. Pharmacother. 5(7), 1621-1633 (2004)
19. Wu X, Rubin M, Fan Z et al.: Involvement of p27kip1 in G1 arrest mediated by an antiepidermal growth factor receptor monoclonal antibody. Oncogene 12, 1397-1403 (1996)
20. Peng D, Fan Z, Lu Y, Deblasio T, Scher H, Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56, 3666-3669 (1996)
21. Perrotte P, Matsumoto T, Inoue K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999)
22. Bruns CJ Harbison MT, Davis DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6, 1936-48 (2000)
23. Ciardiello F, Bianco R, Damiano V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6, 3739-347 (2000)
24. Inoue K, Slaton JW, Perrotte P et al.: Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874-84 (2000)
25. Ciardiello F, Bianco R, Damiano V et al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5, 909-916 (1999)
26. Prewett MC, Hooper AT, Bassi R et al.: Enhanced antitumor activity of antiepidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal cancer xenografts. Clin. Cancer Res. 8(5), 994-1003 (2002)
27. Saleh MH, Raisch KP, Stackhouse MA et al.: Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm 14, 451-463 (1999)
28. Milas L, Mason K, Hunter N et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6, 701-708 (2000)
29. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 15, 1935-1940 (1999)
30. Bianco C, Bianco R, Tortora G et al.: Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus Type I protein kinase A antisense oligonucleotide. Clin. Cancer Res. 6, 4343-4350 (2000)
31. Huang S-M, Harari P: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174 (2000)
32. Debaldo C, Pierga JY, Dieras V et al.: Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of Phase I study. Eur. J. Cancer Suppl. 1(5), [Abstract] 552 (2003)
33. Folprecht G, Lutz MP, Schoeffski P et al.: Pharmacokinetic (PK) evaluation of cetuximab in combionation with weekly irinotecan (CPT-11) and 24h infusional 5- FU/folinic acid /FA) as first-line treatment in patients with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 22, [Abstract] 890 (2003)
34. Baselga J, Pfister D, Cooper MR et al.: Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000)
35. Robert F, Ezekiel MP, Spencer SA et al.: Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19(13), 3234-3243 (2001)
36. Saltz L, Rubin M, Hochster H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 20, [Abstract] 7 (2001)
37. Saltz L, Meropol NJ, Loeher PJ et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004)
38. Lenz HJ, Mayer RJ, Gold PJ et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. 23, [Abstract] 3510 (2004)
39. Cunningham D, Humblet Y, Siena S et al.: A randomized comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004)
40. Rosemberg AH, Loeherer PJ, Needle MN et al.: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that express the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 21, [Abstract] 536 (2002)
41. Folprecht G, Lutz MP, Schoeffski P et al. : Cetuximab/irinotecan/high dose 5- Fluorouracil/leucovorin(HD-5-FU/LV) in first line therapy of metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 22 [Abstract] 890 (2003)
42. Raoul JL, Van Laethem J-L, Mitry E et al.: Phase II study of cetuximab combined with FOLFIRI (biweekly irinotecan plus infusional 5-FU and foloic acid (FA) in patients with metastatic epidermal growth factor receptor (EGFR)- expressing colorectal cancer (CRC). Eur. J. Cancer Suppl. 1, [Abstract] S89 (2003)
43. Tabernero JM, Van Cutsem E, Sastre J et al.: An international Phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 23, [Abstract] 3512 (2004)
44. Gustafson NF, Saltz L, Cunnincham D et al.: Safety profile of cetuximab in patients with metastatic colorectal cancer. Am. Soc. Clin. Oncol. Gastrointest. Can. Symposium. [Abstract] 237 (2004)
45. Holliwood E: Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC, C2250-C2235 (2002)
46. Cohen RB, Falcey JW, Paulter WJ, Fetzer KM, Waksal HW: Safety profile of the monoclonal antibody IMC-C225, an antiepidermal growth factor receptor ( EGFR) used in the treatment of EGFR-positive tumors. Proc. Am. Soc. Clin. Oncol. 19, [Abstract] 1862 (2000)
47. Busam KJ, Capodieci P, Motzer R et al.: Cutaneous side effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 144, 1169-1176 (2001)
48. Saltz L Kies M, Abbruzzese JL, Azarnia N, Needle M: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. 22, [Abstract] 817 (2003)
49. Khazaeli MB, Lossuglio AF, Falcey JW et al.: Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor positive tumors. Proc. Am. Soc. Clin. Oncol. 19, [Abstract] 808 (2000)
50. Lee E, Hoff PM: Targeting the Epidermal Growth Factor Receptor: an important incremental step in the battle against colorectal cancer. J Clin. Onco.l. 22(7), 1177-1779 (2004)
51. Barber TD, Vogelstein B, Kingzler KW, Velculescu VE: Somatic mutations of EGFR in colorectal cancer and glioblastomas. N.Engl J. Med. 351, 2883 (2004)